Literature DB >> 29101607

Development of a high risk pancreatic screening clinic using 3.0 T MRI.

Chad A Barnes1, Elizabeth Krzywda1, Shannon Lahiff1, Dena McDowell1, Kathleen K Christians1, Paul Knechtges2, Parag Tolat2, Mark Hohenwalter2, Kulwinder Dua3, Abdul H Khan3, Douglas B Evans1, Jennifer Geurts1, Susan Tsai4.   

Abstract

Selective screening for pancreatic cancer (PC) has been proposed. We describe the establishment of a comprehensive multidisciplinary screening program using 3.0 T MRI. Criteria for screening included the presence of PC in: ≥ 2 first degree relatives (FDR), 1 FDR and 1 s degree relative (SDR), ≥ 3 any degree relatives (ADR), or any known hereditary cancer syndrome with increased PC risk. Imaging with 3.0 T MRI was performed routinely and endoscopic ultrasound was used selectively. Screening was completed in 75 patients (pts). Hereditary cancer syndromes were present in 42 (56%) of the 75 pts: BRCA2 (18), ATM (8), BRCA1 (6), CDKN2A (4), PALB2 (3), Lynch (2), and Peutz-Jeghers (1). A family history of PC was present in ≥ 2 FDR in 12 (16%) pts, 1 FDR and 1 SDR in 5 (7) pts, and ≥ 3 ADR in 16 (21%) pts. Of the 65 pts who received screening MRI, 28 (43%) pts had pancreatic cystic lesions identified, including 1 (1%) patient in whom a cholangiocarcinoma was diagnosed as well. No patient underwent surgical resection. Using a 3.0 T MRI to screen patients at high risk for developing PC identified radiographic abnormalities in 43% of patients, which were stable on subsequent surveillance. Specific guidelines for the frequency of surveillance and indications for surgery remain areas of active investigation as the global experience with high risk screening continues to mature.

Entities:  

Keywords:  Familial pancreatic cancer; High risk; Pancreas cancer screening

Mesh:

Year:  2018        PMID: 29101607     DOI: 10.1007/s10689-017-0057-z

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  33 in total

1.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Authors:  Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

Review 2.  ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.

Authors:  Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt
Journal:  Am J Gastroenterol       Date:  2015-02-03       Impact factor: 10.864

3.  Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer.

Authors:  T A Brentnall; M P Bronner; D R Byrd; R C Haggitt; M B Kimmey
Journal:  Ann Intern Med       Date:  1999-08-17       Impact factor: 25.391

4.  Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients.

Authors:  Chunling Hu; Steven N Hart; William R Bamlet; Raymond M Moore; Kannabiran Nandakumar; Bruce W Eckloff; Yean K Lee; Gloria M Petersen; Robert R McWilliams; Fergus J Couch
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-10-19       Impact factor: 4.254

5.  Increased Prevalence of Precursor Lesions in Familial Pancreatic Cancer Patients.

Authors:  Chanjuan Shi; Alison P Klein; Michael Goggins; Anirban Maitra; Marcia Canto; Syed Ali; Richard Schulick; Emily Palmisano; Ralph H Hruban
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

6.  The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer.

Authors:  J W Poley; I Kluijt; D J Gouma; F Harinck; A Wagner; C Aalfs; C H J van Eijck; A Cats; E J Kuipers; Y Nio; P Fockens; M J Bruno
Journal:  Am J Gastroenterol       Date:  2009-06-02       Impact factor: 10.864

7.  American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.

Authors: 
Journal:  J Clin Oncol       Date:  2003-04-11       Impact factor: 44.544

8.  Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer.

Authors:  P Langer; P H Kann; V Fendrich; N Habbe; M Schneider; M Sina; E P Slater; J T Heverhagen; T M Gress; M Rothmund; D K Bartsch
Journal:  Gut       Date:  2009-05-25       Impact factor: 23.059

9.  Variation in precursor lesions of pancreatic cancer among high-risk groups.

Authors:  Thomas P Potjer; Ingrid Schot; Peter Langer; Johannes T Heverhagen; Martin N J M Wasser; Emily P Slater; Günter Klöppel; Hans M Morreau; Bert A Bonsing; Wouter H de Vos Tot Nederveen Cappel; Mathias Bargello; Thomas M Gress; Hans F A Vasen; Detlef K Bartsch
Journal:  Clin Cancer Res       Date:  2012-11-21       Impact factor: 12.531

10.  Multiple small "imaging" branch-duct type intraductal papillary mucinous neoplasms (IPMNs) in familial pancreatic cancer: indicator for concomitant high grade pancreatic intraepithelial neoplasia?

Authors:  D K Bartsch; K Dietzel; M Bargello; E Matthaei; G Kloeppel; I Esposito; J T Heverhagen; T M Gress; E P Slater; P Langer
Journal:  Fam Cancer       Date:  2013-03       Impact factor: 2.375

View more
  5 in total

1.  The importance of a well-structured pancreatic screening program for familial and hereditary pancreatic cancer.

Authors:  Hans F A Vasen
Journal:  Fam Cancer       Date:  2018-01       Impact factor: 2.375

2.  Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model.

Authors:  Mary Linton B Peters; Andrew Eckel; Anna Lietz; Claudia Seguin; Peter Mueller; Chin Hur; Pari V Pandharipande
Journal:  Pancreatology       Date:  2022-05-31       Impact factor: 3.977

Review 3.  Magnetic Fields and Cancer: Epidemiology, Cellular Biology, and Theranostics.

Authors:  Massimo E Maffei
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

4.  Long-term yield of pancreatic cancer surveillance in high-risk individuals.

Authors:  Kasper A Overbeek; Iris J M Levink; Brechtje D M Koopmann; Femme Harinck; Ingrid C A W Konings; Margreet G E M Ausems; Anja Wagner; Paul Fockens; Casper H van Eijck; Bas Groot Koerkamp; Olivier R C Busch; Marc G Besselink; Barbara A J Bastiaansen; Lydi M J W van Driel; Nicole S Erler; Frank P Vleggaar; Jan-Werner Poley; Djuna L Cahen; Jeanin E van Hooft; Marco J Bruno
Journal:  Gut       Date:  2021-04-05       Impact factor: 31.793

5.  Genetic counselling and personalised risk assessment in the Australian pancreatic cancer screening program.

Authors:  Tanya Dwarte; Skye McKay; Amber Johns; Katherine Tucker; Allan D Spigelman; David Williams; Alina Stoita
Journal:  Hered Cancer Clin Pract       Date:  2019-10-23       Impact factor: 2.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.